---
title: "Ascendis Pharma A/S (ASND.US) — 公司概況"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/ASND.US/overview.md"
symbol: "ASND.US"
name: "Ascendis Pharma A/S"
parent: "https://longbridge.com/zh-HK/quote/ASND.US.md"
datetime: "2026-04-15T16:06:52.844Z"
locales:
  - [en](https://longbridge.com/en/quote/ASND.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ASND.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ASND.US/overview.md)
---

# Ascendis Pharma A/S (ASND.US) — 公司概況

## 基本資訊

| 項目 | 詳情 |
|------|--------|
| 行業 | 生物技術 |
| 交易所 | US Market |
| 地址 | Tuborg Boulevard 12, Hellerup, Capital Region of Denmark, Denmark |
| 官網 | [ascendispharma.com](https://ascendispharma.com) |

## 公司簡介

Ascendis Pharma A/S 是一家生物制藥公司，專注于開發基于 TransCon 的療法，以滿足歐洲、美國及國際上的未滿足醫療需求。該公司提供 SKYTROFA，用于治療生長激素缺乏的兒童患者；以及 YORVIPATH，這是一種每日一次的皮下注射，用于治療慢性甲狀旁腺功能減退的成人。它還在臨床開發中開發三種獨立的內分泌罕見疾病產品候選藥物，並專注于推進腫瘤治療候選藥物。該公司成立于 2006 年，總部位于丹麥赫勒魯普

## 核心管理層

| 名稱 | 職位 |
|------|-------|
| Jan Moller Mikkelsen | President, CEO, Member of Executive Board & Executive Director |
| Albert Cha | Independent Chairman |
| Scott T. Smith | CFO, Executive VP & Member of Executive Board |
| Pedersen Anni Lotte Kirstine Sonderbjerg | Executive VP, Chief Administrative Officer & Member of the Executive Board |
| Michael Wolff Jensen | Executive VP, Chief Legal Officer & Member of the Executive Board |
| Mads Bodenhoff | Senior VP, Head of Finance & Principal Accounting Officer |
| Lars Holtug | Independent Director |
| Lisa Bright Morrison | Independent Director |
| Siham Imani | Independent Director |

## 主要股東

| 名稱 | 佔比 | 報告日期 |
|------|-------|-------------|
| RA Capital Management, L.P. | 16.64% | 2025-12-31 |
| Westfield Capital Management Company, L.P. | 8.39% | 2025-12-31 |
| Avoro Capital Advisors LLC | 8.27% | 2025-12-31 |
| FMR LLC | 6.72% | 2025-12-31 |
| Janus Henderson Group plc | 6.57% | 2025-12-31 |
| T. Rowe Price Group, Inc. | 5.24% | 2025-12-31 |
| Artisan Partners Limited Partnership | 5.22% | 2025-12-31 |
| Capital Research and Management Company | 5.05% | 2025-12-31 |
| Massachusetts Financial Services Company | 3.05% | 2025-12-31 |
| Wellington Management Group LLP | 2.85% | 2025-12-31 |

## 業務構成

| 業務線 | 營收 | 佔比 |
|---------|---------|-------|
| 生物技術 | 720132000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Ascendis Pharma A/S Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "生物技術",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## 地區分佈

| 地區 | 營收 | 佔比 |
|--------|---------|-------|
| 美國 | 546388000 | 75.87% |
| Europe (excludes Denmark) | 108046000 | 15% |
| 世界其他地區 | 52798000 | 7.33% |
| 丹麥 | 12900000 | 1.79% |


---

> **免責聲明: 本文僅供參考，不構成任何投資建議。**